Developing Multimodal Therapies for Brain Disorders: Proceedings of a Workshop
||November 18, 2016
Note: Proceedings contain the opinion of the presenters, but do NOT reflect the conclusions of the Health and Medicine Division or the National Academies. Learn more about the differences between Reports and Proceedings.
Multimodal therapy approaches that combine interventions aimed at different aspects of disease are emerging as potential—and perhaps essential— ways to enhance clinical outcomes for patients with psychiatric and neurological disorders. Indeed, for most chronic diseases, multiple pathways are involved simultaneously, making it unlikely that a single treatment will prove sufficiently effective, said Robert Califf, commissioner of Food and Drugs at the Food and Drug Administration (FDA). Califf was the keynote speaker at a workshop on multimodality therapies for brain disorders, convened by the National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous Systems Disorders. The workshop brought together key stakeholders to examine the general principles underlying multimodal therapies and to explore challenges, potential barriers, and opportunities for their development from multiple perspectives, including scientific, clinical, regulatory, and financial. These proceedings chronicle the presentations and discussions at the workshop.